Study to Treat Major Depressive Disorder (MDD) With a New Medication

Summary

The purpose of this study is to test the antidepressant effects of Ezogabine in major depressive disorder (MDD). The investigators also aim to determine the safety and tolerability Ezogabine in patients with MDD. The investigators hypothesize that depressive symptoms will be significantly decreased following an 8-week treatment period of the medication compared to baseline.

Timeline

Start

2014-08

Primary completion

2016-12

Completion

2016-12

Drugs

Indications